Blake Insomnia Therapeutics, a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, has submitted its clinical trial application (CTA) for phase II clinical testing to Health Canada.

The phase II clinical trial will investigate the effect of ZLX-1 on insomnia, and is a critical milestone for this novel insomnia treatment on its way to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the phase IIb trial to follow.

“We are thrilled to finally see the the clinical trial taking off,” said Blake Insomnia Therapeutics president and CEO Birger Jan Olsen. “It is an important milestone for the company and also for me personally, as I’ve been looking forward to this moment for quite some time now.”